Literature DB >> 21644108

Possible heart failure associated with pregabalin use: case report.

Gülay Erdoğan1, Dilek Ceyhan, Sacit Güleç.   

Abstract

Pregabalin and gabapentin are widely used analgesic, anticonvulsant and anxiolytic agents as they are relatively reliable and easily tolerated. However, they may cause some side effects such as dizziness, somnolence, dose-dependent peripheral edema, and weight gain, which may cause patients to abandon their use. Furthermore, there are a few reports in the literature addressing elderly patients with serious chronic disease and cardiac history, who develop heart failure during pregabalin application. In this report, we present a patient with no cardiac history treated with 300 mg/kg pregabalin due to neuropathic pain, who developed peripheral and then central edema, which were determined after advanced investigations. After stopping pregabalin, the situation regressed. Then, peripheral edema developed associated with the recommended dose of gabapentin, which was used in place of pregabalin. Despite the lack of any published evidence, the New York Heart Association issued a warning about using caution when prescribing pregabalin to type III-IV heart failure patients. Though the effect mechanisms of pregabalin and gabapentin are not well known, the calcium channel relationship may lead to these side effects. In summary, we believe that pregabalin and gabapentin, which is mostly used nowadays, should be administered with care not only in patients with advanced cardiac pathology but also in all patients, due to the potential side effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21644108

Source DB:  PubMed          Journal:  Agri        ISSN: 1300-0012


  6 in total

1.  Pregabalin for the treatment of generalized anxiety disorder: an update.

Authors:  David S Baldwin; Khalil Ajel; Vasilios G Masdrakis; Magda Nowak; Rizwan Rafiq
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570

Review 2.  Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia.

Authors:  Santosh Bhusal; Sherilyn Diomampo; Marina N Magrey
Journal:  Drug Healthc Patient Saf       Date:  2016-02-17

3.  Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy.

Authors:  Yiheng Pan; Pamela B Davis; David C Kaebler; Robert P Blankfield; Rong Xu
Journal:  Cardiovasc Diabetol       Date:  2022-09-01       Impact factor: 8.949

4.  Pregabalin in neuropathic pain: evidences and possible mechanisms.

Authors:  Vivek Verma; Nirmal Singh; Amteshwar Singh Jaggi
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

5.  Gabapentin induces edema, hyperesthesia and scaling in a depressed patient; a diagnostic challenge.

Authors:  Reza Bidaki; Zahra Sadeghi; Safiye Shafizadegan; Ali Sadeghi; Behrang Khalili; Alireza Haghshenas; Seyyed Mohammad Mahdy Mirhosseini
Journal:  Adv Biomed Res       Date:  2016-01-27

6.  Convulsive Syncope Induced by Ventricular Arrhythmia Masquerading as Epileptic Seizures: Case Report and Literature Review.

Authors:  John Sabu; Kalyani Regeti; Mary Mallappallil; John Kassotis; Hamidul Islam; Shoaib Zafar; Rafay Khan; Hiyam Ibrahim; Romana Kanta; Shuvendu Sen; Abdalla Yousif; Qiang Nai
Journal:  J Clin Med Res       Date:  2016-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.